<DOC>
	<DOCNO>NCT00003203</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin vincristine , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining carboplatin vincristine radiation therapy follow adjuvant chemotherapy may kill tumor cell . PURPOSE : Randomized phase II trial study effectiveness combination chemotherapy plus radiation therapy follow adjuvant chemotherapy treat young patient newly diagnose high-risk CNS embryonal tumor .</brief_summary>
	<brief_title>Carboplatin Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasible dose duration carboplatin combine craniospinal local radiotherapy adjuvant chemotherapy child newly diagnose , high-risk CNS embryonal tumor ( Phase I complete 11-25-03 ) . - Determine feasibility administer cyclophosphamide vincristine without cisplatin concurrent carboplatin , vincristine , radiotherapy patient . - Determine overall individual toxicity rate regimen patient . - Determine complete response rate patient treat regimen . - Obtain preliminary estimate event-free survival patient treat regimen . - Determine prognostic significance enhance tumor completion radiotherapy event-free survival patient . OUTLINE : This pilot , dose-escalation study carboplatin . ( Phase I complete 11-25-03 . ) Within 31 day definitive surgery , patient receive vincristine IV weekly 6 week carboplatin IV 15-20 minute ( completion vincristine infusion ) 5 day week 6 week . Patients undergo radiotherapy ( 1-4 hour carboplatin infusion ) 5 day week 6 week . Cohorts 6-12 patient receive escalate dos carboplatin maximum tolerate dose ( MTD ) determine . The MTD define dose 3 12 patient experience dose-limiting toxicity . ( Phase I complete 11-25-03 . ) At 6 week completion radiotherapy , patient assign arm II adjuvant/maintenance chemotherapy . ( Arm I close accrual 11-25-03 . ) - Arm I ( closed accrual 11-25-03 ) : Patients receive cyclophosphamide IV 1 hour day 0 1 , vincristine IV day 0 7 , filgrastim ( G-CSF ) IV subcutaneously ( SC ) begin day 2 continue least 10 day blood count recover . - Arm II : Patients receive cyclophosphamide IV 1 hour day 1 2 , vincristine IV day 0 7 , cisplatin IV 6 hour day 0 , G-CSF IV SC begin day 3 continue least 10 day blood count recover . In arm , adjuvant/maintenance chemotherapy repeat every 4 week 6 course . Patients follow every 3 month 8 month , every 4 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 162 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven highrisk CNS embryonal tumor , include : Primitive neuroectodermal tumor Atypical teratoid/rhabdoid tumor Medulloblastoma Desmoplastic medulloblastoma Ependymoblastoma Medullomyoblastoma Spongioblastoma Spongioblastoma polare Primitive polar spongioblastoma Neuroepitheliomatous neoplasm Medulloepithelioma Neuroblastoma Pineoblastoma No bone marrow involvement bone metastases No M4 disease M3 disease must evidence tumor spinal MRI PATIENT CHARACTERISTICS : Age : 3 21 diagnosis Performance status : Not specify Life expectancy : At least 8 week Hematopoietic : Absolute neutrophil count great 1,500/mm^3 Platelet count least 100,000/mm^3 ( transfusion independent ) Hemoglobin least 10.0 g/dL ( pack red blood cell transfusion allow ) Hepatic : Bilirubin le 1.5 mg/dL SGOT/SGPT le 2.5 time normal Renal : Creatinine le 1.5 time upper limit normal OR Creatinine clearance radioisotope glomerular filtration rate least 70 mL/min PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Prior definitive surgery allow</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>untreated childhood medulloblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
</DOC>